MX2022013323A - Compuestos triciclicos como inhibidores de nlrp3. - Google Patents

Compuestos triciclicos como inhibidores de nlrp3.

Info

Publication number
MX2022013323A
MX2022013323A MX2022013323A MX2022013323A MX2022013323A MX 2022013323 A MX2022013323 A MX 2022013323A MX 2022013323 A MX2022013323 A MX 2022013323A MX 2022013323 A MX2022013323 A MX 2022013323A MX 2022013323 A MX2022013323 A MX 2022013323A
Authority
MX
Mexico
Prior art keywords
sup
nlrp3
inhibitors
compounds
tricyclic compounds
Prior art date
Application number
MX2022013323A
Other languages
English (en)
Inventor
Gool Michiel Luc Maria Van
Daniel Oehlrich
Mohamed Lamkanfi
Opdenbosch Nina Van
Alejandro Diéguez-Vázquez
Roman Santiago Cañellas
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2022013323A publication Critical patent/MX2022013323A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos novedosos para su uso como inhibidores de la producción del inflamasoma NLRP3, en donde tales compuestos son como se definen mediante los compuestos de formula (I) (ver Fórmula) (I) y en donde R1, R2 y R3 se definen en la descripción, y donde los compuestos pueden ser útiles como medicamentos, por ejemplo, para su uso en el tratamiento de una enfermedad o trastorno que está asociado con la actividad del inflamasoma NLRP3.
MX2022013323A 2020-04-23 2021-04-23 Compuestos triciclicos como inhibidores de nlrp3. MX2022013323A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382332 2020-04-23
PCT/EP2021/060649 WO2021214284A1 (en) 2020-04-23 2021-04-23 Tricyclic compounds as inhibitors of nlrp3

Publications (1)

Publication Number Publication Date
MX2022013323A true MX2022013323A (es) 2022-11-30

Family

ID=70480193

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013323A MX2022013323A (es) 2020-04-23 2021-04-23 Compuestos triciclicos como inhibidores de nlrp3.

Country Status (10)

Country Link
US (1) US20230203064A1 (es)
EP (1) EP4139312A1 (es)
JP (1) JP2023523418A (es)
KR (1) KR20230005252A (es)
CN (1) CN115461345A (es)
AU (1) AU2021260115A1 (es)
BR (1) BR112022020798A2 (es)
CA (1) CA3176029A1 (es)
MX (1) MX2022013323A (es)
WO (1) WO2021214284A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023044043A1 (en) * 2021-09-17 2023-03-23 Denali Therapeutics Inc. Compounds, compositions and methods
WO2023118521A1 (en) 2021-12-22 2023-06-29 Ac Immune Sa Dihydro-oxazol derivative compounds
WO2023156643A1 (en) * 2022-02-21 2023-08-24 Sanofi Thienopyrrolotriazine compounds, their preparation and their therapeutic use
US20240034735A1 (en) 2022-07-14 2024-02-01 Ac Immune Sa Novel compounds
US20240101563A1 (en) 2022-07-28 2024-03-28 Ac Immune Sa Novel compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7157804B2 (ja) 2017-10-17 2022-10-20 ノバルティス アーゲー Ｎｌｒｐ活性に関連する病態を治療するためのスルホンアミド及びその組成物
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
JP2021529187A (ja) 2018-07-03 2021-10-28 ノバルティス アーゲー Ｎｌｒｐモジュレータ
CN112513048A (zh) 2018-07-20 2021-03-16 豪夫迈·罗氏有限公司 作为白细胞介素-1活性抑制剂的磺酰亚胺酰胺类化合物
WO2020021447A1 (en) 2018-07-25 2020-01-30 Novartis Ag Nlrp3 inflammasome inhibitors
US20220098188A1 (en) 2018-08-17 2022-03-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitors

Also Published As

Publication number Publication date
US20230203064A1 (en) 2023-06-29
BR112022020798A2 (pt) 2022-11-29
CN115461345A (zh) 2022-12-09
CA3176029A1 (en) 2021-10-28
JP2023523418A (ja) 2023-06-05
WO2021214284A1 (en) 2021-10-28
AU2021260115A1 (en) 2023-01-05
KR20230005252A (ko) 2023-01-09
EP4139312A1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
MX2022014942A (es) Nuevos compuestos.
MX2022013637A (es) Nuevos compuestos de triazinoindol.
MX2022013323A (es) Compuestos triciclicos como inhibidores de nlrp3.
MX2022012896A (es) Pirrolo[1,2-d][1,2,4]triazin-2-ilacetamidas como inhibidores de la ruta del inflamasoma nlrp3.
MX2022012897A (es) Pirazolo[1,5-d][1,2,4]triazin-5(4h)acetamidas como inhibidores de la ruta del inflamasoma nlrp3.
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
CR20230024A (es) Derivados de quinoxalina como fármacos contra el cáncer
MX2023003459A (es) Nuevos compuestos.
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
MX2022009967A (es) Compuestos para el tratamiento de la infeccion por coronavirus.
MX2023003846A (es) Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
PL1745010T3 (pl) Podstawione pochodne cykloheksylo-1,4-diaminy
MX2023003458A (es) Nuevos compuestos.
MX2023003825A (es) Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados.
MX2023006578A (es) Heteroaril-acetilenos, sus composiciones farmacéuticas y sus aplicaciones terapéuticas.
MX2023010310A (es) Derivados de 4-alcoxi-6-oxo-piridazina que modulan nlrp3.
MX2023010223A (es) Derivados de 4-amino-6-oxo-piridazina que modulan la nlrp3.
MX2023011057A (es) Derivados de indolina como inhibidores de receptores de dominio de discoidina 1 (ddr1) y receptores de dominio de discoidina 2 (ddr2).
DE60228968D1 (de) Deramciclan-enthaltende pharmazeutische zusammensetzung für die behandlung der verringerung kognitiver funktionen und/oder schäden davon
MX2023006231A (es) Inhibidores de enzimas.
MX2023006193A (es) Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina.
MX2022012067A (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad agonista de gpr52.
MX2022011565A (es) Derivados de acido boronico y usos terapeuticos de los mismos.